Dr. Alexandre E. Malek, MD
Infectious Disease (Infectious Disease Physician)
- Medicare participating
At a glance
- Years since graduation
- 14
- In the NPI registry since
- 2018
- Medicare patients seen, 2024
- 106
Licensed in Texas since 2026, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2018Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Infectious Disease Physician primary
LA license 328253 · TX license W6301 (first issued 2026; active) -
Internal Medicine Physician
LA license 328253
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Memorial Hermann - Texas Medical Center Houston, TX
- Willis Knighton Medical Center Shreveport, LA
- Ochsner Lsu Health Shreveport Shreveport, LA
- Ochsner Lsu Health Shreveport-St Mary Medical Cent Shreveport, LA
Medical groups
- Lsu Health Sciences Center Shreveport Faculty Group Practice (571 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 106
- Services billed
- 394
- Patients’ average age
- 64
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 226 | 73 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 68 | 16 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 62 | 61 |
| Established patient office or other outpatient visit, 30-39 minutes | 55 | 33 |
| Established patient office or other outpatient visit, 20-29 minutes | 21 | 14 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 15 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Biktarvy (bictegrav/emtricit/tenofov ala) | 168 |
| Juluca (dolutegravir/rilpivirine) | 59 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Houston, TX | 47 |
| Tivicay (dolutegravir sodium) | 47 |
| Prezcobix (darunavir/cobicistat) | 37 |
| Dovato (dolutegravir sodium/lamivudine) | 34 |
| Odefsey (emtricitab/rilpiviri/tenof ala) | 26 |
| Doxycycline Hyclate Other prescribers in Houston, TX | 24 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Houston, TX | 22 |
| Pifeltro (doravirine) | 19 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 13 companies reported 68 payments worth $1,356 in total to this clinician.
| AbbVie Inc. | $234 |
|---|---|
| Merck Sharp & Dohme LLC | $202 |
| Viiv Healthcare Company | $198 |
| Paratek Pharmaceuticals, Inc. | $176 |
| Gilead Sciences, Inc. | $171 |
| Shionogi Inc | $68.41 |
| Astellas Pharma US Inc | $63.40 |
| Insmed, Inc. | $58.72 |
| Food and Beverage | $1,328 |
|---|---|
| Education | $28.23 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Insmed, Inc. Sep 24, 2025 | Education Brinsupri; Brinsupri · Respiratory · in-kind | $17.38 |
| Merck Sharp & Dohme LLC May 19, 2025 | Education ZERBAXA · INFECTIOUS DISEASE · in-kind | $10.85 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $45,606 in research payments for these studies, mostly to the institutions running them.
- A Study to Assess the Safety and Risk of Hypersensitivity Reactions of Sulbactam-durlobactam in Adults With Acinetobacter Baumannii-calcoaceticus (ABC) Complex Infection
La Jolla Pharmaceutical Company · Recruiting · NCT06746883
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.